TFXTeleflex Incorporated
Is the business good?
The checks split: earnings fully cash-backed (7.0×), but margins compressing.
Operating profit is fully backed by cash. Conversion is improving vs a year ago.
Operating profit is falling even as sales grow, costs are outrunning the top line.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is TFX?
Teleflex Incorporated earns 0.65% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 8.3 points below what the capital costs: growth destroys value
- Operating margin
- 2.0%
Operating margin · Medical Instruments & Supplies median 6.6% · 12 months to Q2 2026
- Cash conversion
- 6.96×
Cash conversion · 0.31× a year ago · operating cash flow covers the operating profit after tax
- Share count, year on year
- −1.5%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | 17% |
| FY2021 | 22% |
| FY2022 | 18% |
| FY2023 | 15% |
| FY2024 | 6.1% |
| FY2025 | 5.9% |
Details›
- Gross margin12 months to Q2 2026
- 55%
- Operating margin12 months to Q2 2026
- 2.0%
- Net margin12 months to Q2 2026
- −46%
- Free cash flow margin
- 7.5%
- R&D as % of revenue
- 7.1%
- Revenue, trailing twelve months
- $2.25B
- Free cash flow, trailing twelve months
- $168M
- Net income, trailing twelve months
- −$1.03B
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 0.65%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Medical Instruments & Supplies
Ranks #10 of 21 by RyuScore